Phase II Trial of SAL0140 Shows Promise for Primary Aldosteronism
A Phase II clinical trial is underway to evaluate the efficacy and safety of SAL0140 at varying doses in patients with primary aldosteronism.
Therapeutic Area
Therapeutic area intelligence for Primary Aldosteronism with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.